ARTICLE | Product Development
A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb
NIH begins ACTIV-5 study of anti-inflammatory mAbs, plus Moderna starts rolling submission in Canada
October 14, 2020 12:40 AM UTC
The launch of NIH’s Phase II ACTIV-5 Big Effect Trial study of anti-inflammatory mAbs Skyrizi from AbbVie and Boehringer and lenzilumab from Humanigen to treat hospitalized COVID-19 patients has coincided with a pause on the agency’s Phase III study of antiviral mAb bamlanivimab from Lilly and AbCellera in the same setting.
The pause puts a third high-profile COVID-19 program in a holding pattern. ...